Evidence map›Paper›PMID 27344955›Full record

ArticleExperimental eye research2016

Protective effects of bestatin in the retina of streptozotocin-induced diabetic mice.

Ahamed Hossain, David Heron, Ian Davenport, Thomas Huckaba, Richard Graves, Tarun Mandal, Syed Muniruzzaman, Shusheng Wang, Partha S Bhattacharjee

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental eye research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Ubenimex combined with Albendazole for the treatment ofFrontiers in veterinary science · 2024
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. In vivo (Athens, Greece)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ahamed HossainDepartment of Biology, Xavier University of Louisiana, New Orleans, LA 70125, USA.
David HeronDepartment of Biology, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Ian DavenportDepartment of Biology, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Thomas HuckabaDepartment of Biology, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Richard GravesCollege of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Tarun MandalCollege of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Syed MuniruzzamanDepartment of Biology, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Shusheng WangCell and Molecular Biology & Ophthalmology, Tulane University, New Orleans, LA 70118, USA.
Partha S BhattacharjeeDepartment of Biology, Xavier University of Louisiana, New Orleans, LA 70125, USA. Electronic address: pbhattac@xula.edu.
Xavier University of Louisiana · USTulane University · US

Funding

Xavier's RCMI Cancer Research ProgramG12MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI D'AMOUR, GENE, WANG, GUANGDI · 2012 to 2018
$15.7M
NIMHD NIH HHS G12 MD007595
6 · The paper itself

Abstract

CD13/APN (aminopeptidase N) was first identified as a selective angiogenic marker expressed in tumor vasculature and is considered a target for anti-cancer therapy. CD13 was also reported to express in non-diabetic, hypoxia-induced retinal neovascularization. Whether diabetes induces upregulation of CD13 expression in the retina is unknown. We hypothesize that at an early stage of non-proliferative diabetic retinopathy (NPDR) characterized by disruption of blood-retinal barrier (BRB) permeability is related to upregulated expression of CD13 because of its known role in extracellular matrix (ECM) degradation. The purpose of this study is to evaluate the role of CD13/APN and the therapeutic efficacy of a CD13/APN inhibitor in a mouse model of streptozotocin-induced NPDR. Hyperglycemic C57Bl/6 mice 26 weeks after streptozotocin (STZ) injection were intravitreally injected with a sustained release formulation of CD13/APN inhibitor bestatin. At 15th day of post-bestatin treatment, mouse retinas were evaluated for vascular permeability by Evans blue dye extravasation assay, fluorescent angiography of retinal vascular permeability and leukostasis. Retinal protein extracts were analyzed by Western blot to determine the effects of bestatin treatment on the expression of CD13/APN related inflammatory mediators of ECM degradation and angiogenesis. Intravitreal bestatin treatment significantly inhibited retinal vascular permeability and leukostasis. This treatment also significantly inhibited retinal expression of CD13, ECM degrading proteases (heparanase and MMP9 and angiogenic molecules (HIF-1α and VEGF). Intravitreal CD13 inhibition may relate to furthering our knowledge on the protective effect of bestatin against diabetic retinal vasculature abnormalities through inhibition of retinal permeability, leukostasis, inflammatory molecules of ECM degradation and angiogenesis.

Indexed as

AnimalsBlotting, WesternCD13 AntigensDiabetes Mellitus, ExperimentalDiabetic RetinopathyDose-Response Relationship, DrugFluorescein AngiographyFundus OculiIntravitreal InjectionsLeucineMaleMiceMice, Inbred C57BLProtease InhibitorsRetinaCD13 AntigensLeucineProtease InhibitorsubenimexBestatinCD13Diabetic retinopathyECMLeukotriene A4 hydrolaseRetina permeability

Identifiers

PMID27344955
PMCPMC5499666
OpenAlexW2469088964

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.